Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease

NCT04387448 is registered in ClinicalTrials.gov with Goldfinch Bio, Inc. as lead sponsor.

NCT NCT04387448
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04387448 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
Lead sponsor
Goldfinch Bio, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
July 28, 2020
Completion date
November 1, 2022
Enrollment
96 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes complications, diabetes mellitus, diabetic nephropathies, endocrine system diseases, glomerulonephritis, glomerulosclerosis, focal segmental, kidney diseases, nephritis, nephrosis, nephrosis, lipoid, urologic diseases